OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple ...
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary clinical efficacy endpoints related to motor ...
The global multicenter Phase I trial of ISM6331 that is enrolling patients in China and the United States has advanced with the dosing of the first patient in this study for the treatment of ...
At the San Antonio Breast Cancer Symposium (SABCS), investigators reported final phase I results of an alpha-lactalbumin (aLA) vaccine designed to help prevent triple-negative breast cancer (TNBC), ...
CHENGDU, China, Oct. 13, 2025 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy ...
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine ...
Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease ...
Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the cell division cycle 7 (CDC7) inhibitor died in a Phase I trial. The trial (NCT05961839) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback